NCT07806331Not yet recruitingPhase 2
Study of TST002 Injection in Postmenopausal Women With Osteoporosis or Low Bone Mass
A Randomized, Double-Blind, Parallel-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TST002 Injection in Postmenopausal Osteoporosis Patients and Middle-Aged to Older Women With Low Bone Mass
Source: ClinicalTrials.gov · Last updated 11 Sept 2026
Brief summary (registry, in English)
This is a randomized, double-blind, placebo- and active-controlled Phase II study evaluating the efficacy and safety of TST002 injection (a humanized monoclonal antibody) in postmenopausal women with osteoporosis or low bone mass, aged 45-80 years. Approximately 110 participants will be randomized 1:1:1:1:1 (stratified by baseline BMD T-score) to one of five arms: TST002 400 mg every 8 weeks (Q8W), TST002 800 mg Q8W, TST002 1200 mg every 12 weeks (Q12W), placebo, or open-label denosumab 60 mg subcutaneously every 24 weeks. The study includes a screening period (Day -28 to Day -1), a main study period (Week 0-24), and an extension period (Week 25-52), with all participants followed through Week 52 (Day 365). The primary objective is to evaluate the effect of repeated IV TST002 infusions on lumbar spine bone mineral density (BMD). Secondary objectives include characterization of pharmacokinetics, pharmacodynamics, immunogenicity, safety, and tolerability.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 110 (estimated)
- First submitted
- 20 Aug 2026
- Start date
- 31 Oct 2026
- Primary completion date
- 30 Apr 2027
- Lead sponsor
- Transcenta Therapeutics (Hangzhou) Co., Ltd.
- Diseases
- Osteoporosis
- NCT number
- NCT07806331
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 110
- From 31 Oct 2026 to the primary completion date, 30 Apr 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior hip fracture.
- Prior osteoporosis therapy (incl. trial participation) within protocol-specified washout windows (IV bisphosphonates, oral bisphosphonates, denosumab/cathepsin K inhibitors, tibolone/cinacalcet/calcitonin, teriparatide/PTH analogs, systemic estrogen/SERMs, strontium ranelate/fluoride, hormonal castration therapy, systemic glucocorticoids ≥5 mg/day prednisone-equivalent for \>14 days) - see protocol for exact windows per agent.
- History of MI, or serious cardiac disease (CAD, NYHA class II-IV heart failure) within 6 months before screening.
- Malignancy within 5 years before screening (except cured skin squamous/basal cell carcinoma or documented cured in situ cervical cancer, no recurrence ≥3 months before dosing).
- Active tuberculosis within 6 months before screening.
- Participation in another clinical trial within 30 days or 5 half-lives of the investigational product (whichever longer) before screening.
Other illness
- Known skeletal, endocrine, or rheumatic disease that could confound results (e.g., Paget's disease, osteomalacia, osteopetrosis, osteogenesis imperfecta, sclerosteosis, rheumatoid arthritis, ankylosing spondylitis, Cushing's disease, hyperprolactinemia, uncontrolled thyroid disease, hyper-/hypoparathyroidism, or CN VIII compression hearing loss).
- History of TMJ disorder, TMJ osteonecrosis, or atypical fracture.
- History of stroke (cerebral infarction, ischemic or hemorrhagic).
- Multiple myeloma, primary/metastatic bone malignancy, or history of skeletal radiotherapy.
- Known hypersensitivity to study drug.
- History of solid organ or bone marrow transplant.
- Positive HIV, syphilis, HCV antibody, or HBsAg at screening; or HBcAb-positive with detectable HBV DNA.
- Any other condition the investigator judges unsuitable for participation, a safety risk, or interfering with study assessments/completion.
Lab values
- Hypercalcemia or hypocalcemia (albumin-corrected) at screening.
- Serum 25(OH)D \<20 ng/mL at screening.
- ALT/AST \>3× ULN; ALP \>2.5× ULN; total bilirubin or creatinine \>1.5× ULN at screening.
Other
- BMD T-score ≤-3.50 at lumbar spine, total hip, or femoral neck at screening.
- ≥2 vertebral fractures on screening lateral spine X-ray (investigator-assessed).
Who the study is looking for
- Voluntary signed informed consent; able to walk freely; willing/able to complete all study procedures.
- BMI 18.0-30.0 kg/m² (inclusive); body weight ≥45 kg.
- Postmenopausal women aged 45-80 years (inclusive) at screening, postmenopausal ≥2 years (≥12 consecutive months without spontaneous vaginal bleeding/spotting).
- BMD T-score \<-2.00 at lumbar spine (L1-L4 total), total hip, or femoral neck at screening; OR history of fragility fracture with T-score \<-1.00 at one of these sites (central imaging read).
- At least 2 contiguous evaluable vertebrae (L1-L4) and at least one evaluable hip for DXA assessment.
- No disease, per investigator history/exam/workup, likely to significantly affect the study or increase health risk (documented exceptions permitted with justification).
Age in the registry: 45 years to 80 years · Sex: Female · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.